Cargando…
Self-Assembly Nanostructure of Myristoylated ω-Conotoxin MVIIA Increases the Duration of Efficacy and Reduces Side Effects
Chronic pain is one of the most prevalent health problems worldwide. An alternative to suppress or alleviate chronic pain is the use of peptide drugs that block N-type Ca(2+) channels (Ca(v)2.2), such as ω-conotoxin MVIIA. Nevertheless, the narrow therapeutic window, severe neurological side effects...
Autores principales: | Ding, Xiufang, Wang, Yue, Zhang, Sida, Zhang, Ruihua, Chen, Dong, Chen, Long, Zhang, Yu, Luo, Shi-Zhong, Xu, Jianfu, Pei, Chengxin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144222/ https://www.ncbi.nlm.nih.gov/pubmed/37103368 http://dx.doi.org/10.3390/md21040229 |
Ejemplares similares
-
TAT-Modified ω-Conotoxin MVIIA for Crossing the Blood-Brain Barrier
por: Yu, Shuo, et al.
Publicado: (2019) -
ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential
por: Schroeder, Christina I., et al.
Publicado: (2006) -
Analgesic effect of recombinant GABAergic precursors releasing ω-conotoxin
MVIIA in a model of peripheral nerve injury in rats
por: Jergova, Stanislava, et al.
Publicado: (2022) -
Conotoxin MVIIA improves cell viability and antioxidant system after spinal cord injury in rats
por: Oliveira, Karen M., et al.
Publicado: (2018) -
Macrocyclic Antimicrobial Peptides Engineered from ω-Conotoxin
por: Hemu, Xinya, et al.
Publicado: (2017)